{"analyses":[{"ciLowerLimit":"0.749","ciNumSides":"TWO_SIDED","ciPctValue":"95","ciUpperLimit":"2.722","estimateComment":"Mantel-Haenszel estimate of the common odds ratio for stratified tables is used, with IPI risk and Stage of Disease as stratification factors. An odds ratio (OR) \\> 1 indicates an advantage for VcR-CAP.","groupIds":["OG000","OG001"],"nonInferiorityType":"SUPERIORITY_OR_OTHER","pValue":"0.275","paramType":"Odds Ratio (OR)","paramValue":"1.428","statisticalMethod":"Cochran-Mantel-Haenszel Chi-Square"}],"classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"204"},{"groupId":"OG001","value":"211"}]}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"228"},{"groupId":"OG001","value":"229"}],"units":"Participants"}],"description":"ORR was defined as complete response (CR) + complete response, unconfirmed (CRu) + partial response (PR) as determined by the Independent Review Committee. Response assessment was carried out every 6 weeks for 18 weeks; thereafter, every 8 weeks until PD/initiation of alternate therapy/withdrawal from study/death.","groups":[{"description":"Rituximab 375 mg/m\\^2, Cyclophosphamide 750 mg/m\\^2, Doxorubicin 50 mg/m\\^2, Vincristine 1.4 mg/m\\^2 and Prednisone 100 mg/m\\^2 Rituximab: Rituximab intravenous on Day 1 of a 21 day (3 week) cycle for 6 cycles. Cyclophosphamide: Cyclophosphamide intravenous on Day 1 of a 21 day (3 week) cycle for 6 cycles Doxorubicin: Intravenous on Day 1 of a 21 day (3 week) cycle for 6 cycles Prednisone: Prednisone orally on Day 1 to Day 5 of a 21 day (3 week) cycle for 6 cycles Vincristine: Vincristine intravenous on Day 1 of a 21 day (3 week) cycle for 6 cycles.","id":"OG000","title":"R-CHOP"},{"description":"Rituximab 375 mg/m\\^2, Cyclophosphamide 750 mg/m\\^2, Doxorubicin 50 mg/m\\^2, VELCADE 1.3 mg/m\\^2, and Prednisone 100 mg/m\\^2 Rituximab: Rituximab intravenous on Day 1 of a 21 day (3 week) cycle for 6 cycles. Cyclophosphamide: Cyclophosphamide intravenous on Day 1 of a 21 day (3 week) cycle for 6 cycles Doxorubicin: Intravenous on Day of a 21 day (3 week) cycle for 6 cycles VELCADE: VELCADE intravenous on Days 1,4,8, and 11 of a 21 day (3 week) cycle for 6 cycles Prednisone: Prednisone orally on Day 1 to Day 5 of a 21 day (3 week) cycle for 6 cycles.","id":"OG001","title":"VcR-CAP"}],"paramType":"NUMBER","populationDescription":"The response-evaluable population was defined as all participants who received \\>= 1 dose of study drug, had at least 1 measurable tumor mass (\\>1.5 cm in the longest dimension and \\>1.0 cm in the short axis) at baseline and had at least 1 post-baseline tumor assessment by Independent Review Committee, before any subsequent anti-lymphoma treatment.","reportingStatus":"POSTED","timeFrame":"Median duration of follow-up of 40 months","title":"Overall Response Rate (ORR)","type":"SECONDARY","unitOfMeasure":"Participants"}